Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostatitis.

Michel A Pontari1, Geoffrey F Joyce, Matthew Wise

  • 1Department of Urology, Temple University School of Medicine, Philadelphia, Pennsylvania, USA.

The Journal of Urology
|May 19, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Comment.

The Journal of urology·2026
Same author

An Overview of Farm Investigation Findings Associated with Outbreaks of Shiga Toxin-Producing Escherichia coli Infections Linked to Leafy Greens: 2009-2021.

Journal of food protection·2025
Same author

Towards precision medicine in clinical trials for the treatment of urologic chronic pelvic pain syndrome: lessons from the MAPP Research Network.

Nature reviews. Urology·2025
Same author

Male Chronic Pelvic Pain: AUA Guideline: Part II Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

The Journal of urology·2025
Same author

Male Chronic Pelvic Pain: AUA Guideline: Part III Treatment of Chronic Scrotal Content Pain.

The Journal of urology·2025
Same author

Male Chronic Pelvic Pain: AUA Guideline: Part I Evaluation and Management Approach.

The Journal of urology·2025
Same journal

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

The Journal of urology·2026
Same journal

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The Journal of urology·2026
Same journal

The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

The Journal of urology·2026
Same journal

Let's Shift the Focus from Death to Life after Fournier's Gangrene.

The Journal of urology·2026
Same journal

Endourology and Nephrolithiasis.

The Journal of urology·2026
Same journal

With great cost comes great responsibility: who will own the rising costs of bladder cancer care?

The Journal of urology·2026
See all related articles

The economic burden of prostatitis in the US is significant, costing $84 million annually. Despite decreasing hospitalizations, understanding and treatment gaps suggest potential resource waste in managing this condition.

Area of Science:

  • Urology
  • Health Economics
  • Public Health

Background:

  • Prostatitis represents a significant health concern in the United States.
  • Understanding its economic impact and resource utilization is crucial for effective management.

Purpose of the Study:

  • To quantify the burden of prostatitis in the US.
  • To identify trends in healthcare resource utilization.
  • To estimate the economic impact of prostatitis.

Main Methods:

  • Analysis of national inpatient hospitalization data.
  • Examination of Medicare beneficiary hospitalization trends.
  • Assessment of outpatient and physician visit data for prostatitis.
  • Review of medication use and associated costs.

Related Experiment Videos

Main Results:

  • National inpatient hospitalizations for prostatitis decreased by 21% (1994-2000).
  • Medicare beneficiaries had higher hospitalization rates (2-2.5x) with a 42% decrease (1992-2001).
  • Annualized prostatitis visit rate was 1,798/100,000 population; $84 million spent annually (excluding pharmaceuticals).
  • Quinolones were the most common medication; 14% of privately insured men missed work.

Conclusions:

  • Prostatitis diagnosis and management cost $84 million annually in the US (excluding pharmaceuticals), with costs potentially increasing.
  • Gaps in understanding prostatitis diagnosis and treatment may lead to inefficient resource allocation.
  • Further research is needed to optimize prostatitis care and reduce associated expenditures.